Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04864392 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 576
- Enrollment target
NCT04864392: Clinical Trial Phase 2 study, sponsored by Novartis Pharmaceuticals.
NCT04864392 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 576 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (333% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04864392, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 576 participants
- Enrollment target
Study Summary
This was a multicenter, randomized, double-blind, placebo-controlled Phase IIb study evaluating intra-articular LNA043 in patients with knee osteoarthritis.
Primary Outcome
The cartilage thickness in the cMTFC of the target knee was assessed by quantitative Magnetic Resonance Imaging (qMRI). The change from baseline at Week 104 was calculated. A negative change from baseline indicated a reduction in the cartilage thickness
Interventions
- DRUG Placebo
- DRUG LNA043
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 576 participants |
| Start Date | 2021-05-31 |
| Est. Completion | 2025-05-29 |
| Phase | Phase 2 |
Why NCT04864392 stopped before completion
NCT04864392 is an interventional study that assigns participants to a tested intervention. The registered 576 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (333% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04864392 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04864392 about?
NCT04864392 is a clinical study titled "Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis". This was a multicenter, randomized, double-blind, placebo-controlled Phase IIb study evaluating intra-articular LNA043 in patients with knee osteoarthritis.
What is the current status of trial NCT04864392?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 576 participants. The study started on 2021-05-31. Estimated completion is 2025-05-29.
What interventions are being tested in trial NCT04864392?
The interventions under investigation include: Placebo (DRUG), LNA043 (DRUG).
Who is sponsoring clinical trial NCT04864392?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04864392's enrollment target sits among peer trials
576 59th of 2000 higher than 1,942 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04931810 · 576 participants · NA
Urban and Reservation Implementation of All Nations Breath of Life
- NCT05179369 · 576 participants · NA
Well-Mama Community Doula Navigator Study
- NCT06398509 · 576 participants · NA
A Primary Care Based Intervention to Prevent Childhood Obesity Among Low-income Latino Children
- NCT02610439 · 575 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI